Multiple recent studies have shown that the upregulation of death receptors, in particular DR5, by other agents such as proteosome inhibitors (44), amiodorone (45), arsenic trioxide (46), and platinum-based chemotherapies (47), can sensitize TRAIL-resistant glioma cell lines to TRAIL-induced cellular death and the use of sensitizers that can upregulate DR5 expression may allow for the selective death of glioma, sparing normal human astrocytes. The gene discussed is TNFRSF10B; the disease is glioma.